Literature DB >> 18001828

Development of lipid particles targeted via sugar-lipid conjugates as novel nuclear gene delivery system.

Tomoya Masuda1, Hidetaka Akita, Takashi Nishio, Kenichi Niikura, Kentaro Kogure, Kuniharu Ijiro, Hideyoshi Harashima.   

Abstract

Efficient nuclear gene delivery is essential for successful gene therapy. This study developed a novel system that mimics the mechanism of nuclear entry of adenovirus (Ad) by means of a Multifunctional Envelope-type Nano Device (MEND). In this system, plasmid DNA (pDNA) was condensed with polycation, followed by encapsulation in a lipid membrane. To target MEND to the nuclear pore complex (NPC), sugar served as a NPC-mediated nuclear targeting device was modified on the surface of the lipid envelope. This was accomplished via synthesis of a sugar-cholesterol conjugate. After binding of the MEND to the NPC, the pDNA core was transferred into the nucleus in conjunction with a breakdown of the lipid envelope. Sugar-modified MEND showed higher transfection efficiency compared with unmodified MEND, in non-dividing and dividing cells. Confocal microscopy confirmed that nuclear transfer of pDNA was improved by sugar modification of MEND. Furthermore, destabilization of the lipid envelope significantly enhanced transfection activity: therefore, nuclear-delivery efficiency was closely related to lipid envelope stability. Moreover, quantitative evaluation of cellular uptake and nuclear transfer processes by real-time PCR confirmed that the surface sugars affected nuclear transfer, but not cellular uptake. In summary, a novel system for the nuclear delivery of pDNA was successfully developed by using a sugar-modified MEND and by optimizing the lipid envelope stability.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18001828     DOI: 10.1016/j.biomaterials.2007.09.039

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  7 in total

1.  Combinatorial evaluation of cations, pH-sensitive and hydrophobic moieties for polymeric vector design.

Authors:  Sharon Y Wong; Nimil Sood; David Putnam
Journal:  Mol Ther       Date:  2009-01-13       Impact factor: 11.454

Review 2.  Composite nanoparticles for gene delivery.

Authors:  Yuhua Wang; Leaf Huang
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

3.  A novel camptothecin derivative incorporated in nano-carrier induced distinguished improvement in solubility, stability and anti-tumor activity both in vitro and in vivo.

Authors:  Min Han; Cai-Xia He; Qiu-Li Fang; Xiao-Chun Yang; Yuan-Yuan Diao; Dong-Hang Xu; Qiao-Jun He; Yong-Zhou Hu; Wen-Quan Liang; Bo Yang; Jian-Qing Gao
Journal:  Pharm Res       Date:  2008-12-02       Impact factor: 4.200

4.  A novel hydrolysis-resistant lipophilic folate derivative enables stable delivery of targeted liposomes in vivo.

Authors:  Yifei Huang; Tan Yang; Wendian Zhang; Yao Lu; Peng Ye; Guang Yang; Bin Li; Shibo Qi; Yong Liu; Xingxing He; Robert J Lee; Chuanrui Xu; Guangya Xiang
Journal:  Int J Nanomedicine       Date:  2014-09-29

Review 5.  Multiple cues on the physiochemical, mesenchymal, and intracellular trafficking interactions with nanocarriers to maximize tumor target efficiency.

Authors:  Sang-Woo Kim; Dongwoo Khang
Journal:  Int J Nanomedicine       Date:  2015-06-17

Review 6.  Enabling cytoplasmic delivery and organelle targeting by surface modification of nanocarriers.

Authors:  Alessandro Parodi; Claudia Corbo; Armando Cevenini; Roberto Molinaro; Roberto Palomba; Laura Pandolfi; Marco Agostini; Francesco Salvatore; Ennio Tasciotti
Journal:  Nanomedicine (Lond)       Date:  2015-07       Impact factor: 5.307

7.  Co-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo.

Authors:  Tan Yang; Bin Li; Shibo Qi; Yong Liu; Yongkang Gai; Peng Ye; Guang Yang; Wendian Zhang; Peng Zhang; Xingxing He; Weijie Li; Zhiping Zhang; Guangya Xiang; Chuanrui Xu
Journal:  Theranostics       Date:  2014-08-24       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.